Candriam S.C.A. Bellus Health Inc. Transaction History

Candriam S.C.A.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2020 Oct 19, 2020	SELL	$2.14 - $12.02 $817,507 - $4.59 Million	-382,013 Closed	0 $0
Q2 2020 Jul 23, 2020	BUY	$8.88 - $11.15 $3.39 Million - $4.26 Million	382,013 New	382,013 $3.93 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.